TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Apr 03, 2023 13:06 JST
Source:
Eisai
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
TOKYO, Apr 03, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system. This clinical research will be conducted by the National Cancer Center Hospital.
The "Patient-Proposed Healthcare Services" system is a system under which medical treatment using unapproved drugs not covered by insurance is applied for to the government based on the patient's request, and is conducted as a clinical trial to confirm safety and efficacy. Under the terms of the agreement, Eisai will provide tazemetostat free of charge to the National Cancer Center Hospital as the drug to be used in "A clinical trial of Tazemetostat for pediatric and AYA* patients with malignant tumors which have no standard of care or and which is refractory to standard of care: Patients-Proposed Healthcare Service" to be conducted by the hospital under this program.
Researched and developed by Eisai and Epizyme, Inc.,** an Ipsen (Headquarters: France) company, tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process.1 Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of "relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)" in 2021, and manufactures and distributes the product.
Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to expanding the potential clinical benefits of tazemetostat for cancer treatment, as it seeks to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families and healthcare professionals.
*AYA (Adolescent & Young Adult): Patients between the ages of 15 and 39.
**Acquired by Ipsen in 2022
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
For more information, visit www.eisai.com/news/2023/news202326.html.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
September 21 2023 11:26 JST
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
September 12 2023 18:05 JST
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
August 04 2023 12:04 JST
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
July 20 2023 10:23 JST
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
July 12 2023 09:05 JST
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
July 07 2023 12:21 JST
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
June 30 2023 10:08 JST
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City
June 22 2023 16:08 JST
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
June 12 2023 09:13 JST
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
June 08 2023 12:32 JST
More Press release >>
Latest Press Release
Value Research Center (VRC) at SSUNGA78: 'How Purpose, Value, and Impact will Drive a Sustainable Post- SDG Future'
Sep 22, 2023 21:00 JST
TOYOTA GAZOO Racing returns to South American roads
Sep 22, 2023 18:26 JST
Fujitsu marks next stage of "Work Life Shift" with new corporate hubs in Tokyo area to boost productivity, data-driven management
Sep 22, 2023 16:20 JST
Fujitsu and Hokuhoku Financial Group launch trials for generative AI to streamline operations for Hokuriku Bank and Hokkaido Bank
Sep 22, 2023 12:32 JST
Innovative MedTech Welcomes Visionary Frederick Schilling to its Corporate Advisory Board
Sep 21, 2023 22:30 JST
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Sep 21, 2023 12:26 JST
JCB and BNI Launch the BNI JCB Ultimate Card
Sep 21, 2023 09:00 JST
Takasago Hydrogen Park, the World's First Integrated Validation Facility for Technologies from Hydrogen Production to Power Generation, Enters Full-Scale Operation
Sep 20, 2023 19:05 JST
HRC and Takaaki Nakagami Agree to Renew Contract
Sep 20, 2023 15:24 JST
Lexus Presents the Theme of Diversification and Electrification Aiming to Deliver New Value to Customers
Sep 20, 2023 11:22 JST
Hitachi Industrial Products to Launch High-capacity Multi-port EV Charger
Sep 19, 2023 20:06 JST
Honda and Toray Begin Joint Demonstration of Closed-loop Recycling of Nylon Resin
Sep 19, 2023 12:07 JST
Fujitsu launches new offering to support sustainable enterprise transformation as Japan's first premium supplier for RISE with SAP
Sep 19, 2023 10:34 JST
Fujitsu strengthens DX consulting capabilities with plans to acquire Australian consultancy MF & Associates - investing for government and healthcare customer success
Sep 19, 2023 10:05 JST
Quantum Computing Startup - Nanofiber Quantum Technologies Secures $8.5m Funding
Sep 18, 2023 04:40 JST
SBM Offshore and MHI Sign Partnership Agreement for FPSO CO2 Capture Solution
Sep 15, 2023 18:51 JST
Fujitsu and the Linux Foundation launch Fujitsu's automated machine learning and AI fairness technologies as Linux Foundation hosted open source projects
Sep 15, 2023 10:23 JST
A New Era: Challenges in Lunar Exploration and Manned Lunar Orbital Base Development
Sep 14, 2023 17:04 JST
MHI Becomes a Full Member of the Japan Center for Engagement and Remedy on Business and Human Rights (JaCER)
Sep 14, 2023 14:45 JST
Fujitsu and Baptist Health South Florida transform operating room scheduling with newly launched solution to boost utilization rates and the financial health of the surgical discipline
Sep 14, 2023 10:33 JST
More Latest Release >>